Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2018-02-27
Target enrollment:
Participant gender:
Summary
This randomized phase I/II trial studies the side effects and best dose of vaccine therapy
and to see how well it works when given together with 1-methyl-D-tryptophan (1-MT) in
treating patients with metastatic breast cancer. Vaccines made from a person's tumor cells
and white blood cells may help the body build an effective immune response to kill tumor
cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute